Last reviewed · How we verify
Sabin IPV + Sabin IPV + bOPV
This is a combination polio vaccine containing inactivated poliovirus vaccine (IPV) derived from Sabin strains plus bivalent oral polio vaccine (bOPV) to provide immunization against poliovirus types 1, 2, and 3.
This is a combination polio vaccine containing inactivated poliovirus vaccine (IPV) derived from Sabin strains plus bivalent oral polio vaccine (bOPV) to provide immunization against poliovirus types 1, 2, and 3. Used for Poliomyelitis prevention in infants and children.
At a glance
| Generic name | Sabin IPV + Sabin IPV + bOPV |
|---|---|
| Sponsor | Zhejiang Provincial Center for Disease Control and Prevention |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The Sabin IPV components deliver inactivated (killed) poliovirus antigens intramuscularly to stimulate systemic humoral immunity, while the bOPV component provides oral immunization with live attenuated poliovirus to induce both systemic and mucosal immunity. This combination approach aims to provide comprehensive protection against all three poliovirus serotypes through complementary immunization routes.
Approved indications
- Poliomyelitis prevention in infants and children
Common side effects
- Local injection site reactions (pain, redness, swelling)
- Fever
- Irritability or fussiness
- Mild gastrointestinal symptoms
Key clinical trials
- Study of Concomitant Administration of the sIPV and DTaP or MMR (PHASE4)
- Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants (PHASE3)
- A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants (PHASE3)
- Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV (PHASE3)
- Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults (PHASE1)
- Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China (PHASE4)
- A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children (PHASE4)
- Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: